淀粉样蛋白PET与18F-FDG-PET在阿尔茨海默病及其他痴呆诊断中的应用
本文基于专家小组讨论,就淀粉样蛋白PET和18F-FDG-PET在神经退行性痴呆诊断中的最佳使用时机、组合及顺序达成共识。作者提出三种主要诊断路径,根据不同临床表现将两种PET生物标志物置于诊断评估的不同位置,以支持专科临床决策并促进进一步研究。
要点
- 淀粉样蛋白PET评估脑内淀粉样蛋白沉积,18F-FDG-PET评估葡萄糖代谢,两者提供互补信息。
- 专家共识提出三种诊断路径,两种PET标志物的顺序取决于临床表现。
- 该算法适用于可获取这些生物标志物的专科临床环境,证据尚不确凿。
核心结论
- 专家小组就淀粉样蛋白PET和18F-FDG-PET在痴呆诊断中的使用达成共识,提出基于临床表现的三种诊断路径。
研究设计与样本
- 基于专家小组讨论的共识文件,依据现有证据和临床经验达成一致。
主要发现
- 淀粉样蛋白PET和18F-FDG-PET提供有价值且互补的信息,但最佳时机、组合和顺序尚缺乏确凿证据。
关键数值与推荐
- 提出三种主要诊断路径,具有不同的生物标志物序列,淀粉样蛋白PET和18F-FDG-PET在诊断评估顺序中位置不同。
临床怎么用
- 该算法可支持可获取这些生物标志物的专科临床环境中的诊断决策。
局限性
- 共识基于现有证据和临床经验,缺乏确凿证据;可能激发进一步研究以优化诊断策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Various biomarkers are available to support the diagnosis of neurodegenerative diseases in clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET, which assesses brain amyloid deposition, and 18F-fluorodeoxyglucose (18F-FDG) PET, which assesses glucose metabolism, provide valuable and complementary information. However, uncertainty remains regarding the optimal timepoint, combination, and an order in which these PET biomarkers should be used in diagnostic evaluations because conclusive evidence is missing. Following an expert panel discussion, we reached an agreement on the specific use of the individual biomarkers, based on available evidence and clinical expertise. We propose a diagnostic algorithm with optimal timepoints for these PET biomarkers, also taking into account evidence from other biomarkers, for early and differential diagnosis of neurodegenerative diseases that can lead to dementia. We propose three main diagnostic pathways with distinct biomarker sequences, in which amyloid-PET and 18F-FDG-PET are placed at different positions in the order of diagnostic evaluations, depending on clinical presentation. We hope that this algorithm can support diagnostic decision making in specialist clinical settings with access to these biomarkers and might stimulate further research towards optimal diagnostic strategies.
引用
- Chételat G, Arbizu J, Barthel H, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurol. 2020. PMID: 33098804. doi:10.1016/S1474-4422(20)30314-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。